The current therapeutic T cell manufacturing process (both for tumor-infiltrating lymphocyte (TIL) and CAR-T cell therapy) includes the selection and activation of T cells from patient apheresis products using CD3/CD28 beads and large clinical scale T cell expansion with high concentrations of IL-2 (36). This evidence concerns the gene IL2 and neoplasm.